2026-08-26T14:23:56-05:00 2025-12-31 872525370 CITRIN COOPERMAN ADVISORS LLC 500 W CUMMINGS PARK SUITE 5650 WOBURN MA 01801 990 2025-01-01 043460220 PROGERIA RESEARCH FOUNDATION INC PROG 9785352594 PO BOX 3453 PEABODY MA 019613453 AUDREY GORDON ESQ PRESIDENT, EXECUTIVE DIRECTOR 9785352594 2026-08-25 1 MARCI COHEN P00830439 7815694700 2026-08-25 2025 2025-03-06 01:10:19Z AUDREY GORDON ESQ 200 LAKE STREET PEABODY MA 01960 7933487 0 X WWW.PROGERIARESEARCH.ORG X 1999 MA DISCOVER TREATMENTS & CURE FOR PROGERIA & ITS AGING-RELATED DISORDERS, INCLUDING HEART DISEASE. 11 10 15 60 0 0 1862392 2020617 0 0 1752842 2433984 35074 3415 3650308 4458016 170155 0 0 0 1604326 1300190 0 0 208071 4127887 2863453 5902368 4163643 -2252060 294373 48028500 49979002 627829 526805 47400671 49452197 X DISCOVER TREATMENTS & CURE FOR PROGERIA & ITS AGING RELATED DISORDERS, INCLUDING HEART DISEASE. 0 1 927130 PROGERIA DRUG TRIAL: THE PROGERIA RESEARCH FOUNDATION AND BOSTON CHILDREN'S HOSPITAL CONTINUE THEIR PARTNERSHIP FOR CONDUCTING CLINICAL DRUG TRIALS FOR CHILDREN WITH PROGERIA. THE CLINICAL TRIAL TEAM: A TEAM OF PROFESSIONALS AT BOSTON CHILDREN'S HOSPITAL AND BRIGHAM & WOMEN'S HOSPITAL WORKING WITH CHILDREN WITH PROGERIA FROM AROUND THE GLOBE. 574601 FUTURE TRIAL EFFORTS: PRF ENGAGES MEMBERS IN THE SCIENTIFIC COMMUNITY WITH EXPERTISE IN VARIOUS DRUGS AND/OR GENETIC THERAPIES FOR THE TREATMENT AND POTENTIAL CURE FOR PROGERIA. THE INVESTIGATION AND COLLABORATIVE EVALUATION OF DRUG THERAPIES IS PURSUED TO IDENTIFY DRUG CANDIDATES/GENETIC THERAPIES THAT CAN LEAD TO FUTURE CLINICAL TRIALS. 1522985 DIAGNOSTIC TESTING: PRF DEVELOPED A DIAGNOSTIC TEST FOR PROGERIA IN THE WAKE OF THE 2003 GENE DISCOVERY SO THOSE WITH PROGERIA, THEIR FAMILIES AND MEDICAL CARETAKERS CAN FOR THE FIRST TIME BE GIVEN A DEFINITIVE SCIENTIFIC DIAGNOSIS. THIS CAN TRANSLATE INTO EARLIER DIAGNOSIS, FEWER MISDIAGNOSES AND EARLY MEDICAL INTERVENTION TO ENSURE A BETTER QUALITY OF LIFE FOR THOSE WITH PROGERIA.(SEE SCHEDULE O FOR CONTINUATION)MEDICAL & RESEARCH DATABASE: THE DATABASE IS A COLLECTION OF MEDICAL RECORDS OF PROGERIA PATIENTS FROM ALL OVER THE WORLD. THE DATA IS RIGOROUSLY ANALYZED TO DETERMINE THE BEST COURSE OF TREATMENTS TO IMPROVE THE PATIENTS' QUALITY OF LIFE. THIS INFORMATION IS INVALUABLE FOR THE ATTENDING PHYSICIAN TO GUIDE THE FAMILY THROUGH THE BEST COURSE OF ACTION. DATABASE MATERIAL WAS USED TO CREATE PRF'S COMPREHENSIVE HEALTHCARE RECOMMENDATIONS HANDBOOK ON PROGERIA AIMED AT OPTIMIZING QUALITY OF LIFE. THE DATABASE WAS ALSO CRITICAL IN DETERMINING THE PRIMARY CLINICAL OUTCOME PARAMETER FOR PAST PROGERIA CLINICAL DRUG TRIALS.PRF TRANSLATION PROGRAM: IN TOUCH WITH THE WORLD. WITH A PROMINENT GLOBAL OUTREACH, PRF ELIMINATES BARRIERS OF COMMUNICATION FOR PATIENTS AND THEIR FAMILIES AROUND THE WORLD. THIS INITIATIVE HAS SUCCEEDED IN TRANSLATING PRF PROGRAM AND MEDICAL CARE MATERIALS INTO OVER 3 DOZEN DIFFERENT LANGUAGES.THE PROGERIA HANDBOOK: A GUIDE FOR FAMILIES AND HEALTH CARE PROVIDERS OF CHILDREN AND YOUNG ADULTS WITH PROGERIA THAT INCLUDES DAILY CARE RECOMMENDATIONS AND EXTENSIVE TREATMENT GUIDELINES. IT IS PUBLISHED IN ENGLISH AND SEVERAL OTHER LANGUAGES TO ALLOW ITS USE THROUGHOUT THE WORLD.INTERNATIONAL PROGERIA REGISTRY: CONSISTS OF CENTRALIZED CONTACT AND OTHER INFORMATION ON CHILDREN AND FAMILIES LIVING WITH PROGERIA. THE REGISTRY PROVIDES DATA ON PATIENT DEMOGRAPHICS AND ASSURES RAPID DISTRIBUTION OF ANY NEW INFORMATION THAT MAY BENEFIT THOSE WITH PROGERIA.SCIENTIFIC CONFERENCES; PRF ORGANIZES MEETINGS THAT BRING TOGETHER SCIENTISTS AND CLINICIANS FROM ALL OVER THE WORLD TO SHARE THEIR EXPERTISE AND CUTTING EDGE SCIENTIFIC DATA, AND FOSTER COLLABORATION IN THE FIGHT AGAINST PROGERIA AND OTHER AGING RELATED CONDITIONS.CLINICAL TRIALS: IN 2025, 7 CHILDREN AND YOUNG ADULTS CAME TO BOSTON TO UNDERGO TESTING AND OBTAIN LONAFARNIB FOR THE PROLON 3 (LONAFARNIB EXTENSION) TRIAL, WHICH ALLOWS CHILDREN AND YOUNG ADULTS WHO ARE UNABLE TO OBTAIN LONAFARNIB IN THEIR HOME COUNTRY TO RECEIVE THIS LIFE EXTENDING TREATMENT THROUGH THIS TRIAL, WHILE ALSO GATHERING IMPORTANT DISEASE-RELATED DATA. IN 2025, THE TEAM CONTINUES TO GATHER DATA FROM THE ONGOING CLINICAL DRUG TRIAL. IN ADDITION, PRF COLLABORATED WITH PRG SCIENCE & TECHNOLOGY IN A TRIAL INVOLVING THE DRUG PROGERININ. TEN CHILDREN AND YOUNG ADULTS CAME TO BOSTON THREE TIMES IN 2025 TO PARTICIPATE IN THE TRIAL. ONE OF THE 10 PARTICIPANTS ONE ALSO PARTICIPATED IN THE PROLON 3 TRIAL SIMULTANEOUSLY DURING ONE OF THE VISITS. 3024716 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 1 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 1 18 0 1 15 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 11 10 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 MA NY CA KY MD PA RI OH MS IL NJ MI AL AK AR CO CT FL GA HI KS ME MN NC NH NM NV OK OR SC TN UT VA WA WV WI DC X GINA INCROVATO DIRECTOR OF OPERATI 9785352594 PO BOX 3453 PEABODY MA 019613453 SCOTT BERNS DIRECTOR 1.00 X 0 0 0 PAULA KELLY TREASURER/DIRECTOR 1.00 X X 0 0 0 KAREN BALLACK DIRECTOR 1.00 X 0 0 0 SANDRA BRESNICK DIRECTOR 1.00 X 0 0 0 KIM PARATORE CLERK/DIRECTOR 1.00 X X 0 0 0 JOHN MAROZZI DIRECTOR 1.00 X 0 0 0 LARRY MILLS DIRECTOR 1.00 X 0 0 0 LIZA MORRIS DIRECTOR 1.00 X 0 0 0 MATTHEW WINTERS DIRECTOR 1.00 X 0 0 0 MARK KIERAN DIRECTOR 1.00 X 0 0 0 ALAN BROGDON DIRECTOR 1.00 X 0 0 0 AUDREY GORDON PRESIDENT & EXECUTIVE DIRECTOR 40.00 X 256385 0 32279 BARBARA NATKE CHIEF BUSINESS OFFICER 40.00 X 319523 0 0 MICHELLE FINO DIRECTOR OF DEVELOPMENT 40.00 X 114478 0 6031 GINA INCROVATO DIRECTOR OF OPERATIONS 40.00 X 113512 0 0 803898 0 38310 4 0 1 0 PPD DEVELOPMENT LP 929 NORTH FRONT STREET WILMINGTON NC 28401 PROGRAM CONSULTANT 261242 MERRILL LYNCH INVESTMENT ADVISORY FEES 225 LIBERTY STREET 37TH FLOOR NEW YORK NY 10281 INVESTMENT ADVISORY 225494 Q SQUARED SOLUTIONS BIOSCIENCE LLC 19 BROWN ROAD ITHACA NY 14850 PROGRAM CONSULTANT 160976 MCGUIREWOODS LLP 800 E CANAL STREET RICHMOND VA 23219 LEGAL 154722 FARBER LLC 4 CORPORATE DRIVE SUITE 287 SHELTON CT 06484 LEGAL 123037 6 140491 98625 1781501 95013 2020617 1874633 1874633 4017747 3458396 559351 559351 559351 20490 140491 17075 3415 3415 4458016 0 0 2437399 608187 492721 43300 72166 556167 216434 275568 64165 27235 19573 4320 3342 25091 13233 8711 3147 83510 49844 24996 8670 280397 207575 72822 64008 64008 225494 225494 402329 361336 19668 21325 108503 38872 37865 31766 43042 43042 55180 11036 41354 2790 9240 7400 1140 700 19319 10457 8862 9394 9394 DRUG TRIAL - OTHER EXPE 864089 864089 FUTURE TRIAL EFFORTS - 338863 338863 SCIENTIFIC WORKSHOP - O 145914 145914 DIAGNOSTIC TESTING 85550 85550 212131 161819 50312 4163643 3024716 930856 208071 5957702 8309848 254124 123656 44104 45299 91446 70999 17277 20447 41506592 41294699 83731 73274 164970 111779 48028500 49979002 462319 415106 165510 111699 627829 526805 X 47140671 49332586 260000 119611 47400671 49452197 48028500 49979002 294373 1757153 0 X 0 1 X 1 0 X 1716497 2155952 1563098 1897466 2024032 9357045 1716497 2155952 1563098 1897466 2024032 9357045 9357045 930288 1032490 1391020 1890780 1874633 7119211 46493405 46493405 62969661 0.14860 0.15370 X SUMMARY OF FACTS AND CIRCUMSTANCES WHICH ESTABLISH THAT THE PROGERIA RESEARCH FOUNDATION (PRF) IS IN THE NATURE OF AN ORGANIZATION THAT IS PUBLICLY SUPPORTED.THE MISSION OF THE PROGERIA RESEARCH FOUNDATION (PRF) IS TO FIND TREATMENTS AND THE CURE FOR HUTCHINSON-GILFORD PROGERIA (PROGERIA) SYNDROME, A FATAL, ULTRA-RARE, "RAPID AGING" DISEASE THAT AFFLICTS CHILDREN WHO, WITHOUT TREATMENT, DIE AT AN AVERAGE AGE OF 14 1/2 YEARS.PRF HAS SOLICITED CONTRIBUTIONS FROM THE GENERAL PUBLIC FROM ITS INCEPTION IN 1999. PRF HAS REPORTED THE FOLLOWING PERCENTAGES OF PUBLIC SUPPORT FOR THE PAST 10 YEARS:2025 = 14.86%2024 = 15.37%2023 = 18.01%2022 = 19.66%2021 = 19.71%2020 = 74.45%2019 = 75.54%2018 = 86.54%2017 = 94.36%2016 = 94.36%2015 = 90.84%AS ILLUSTRATED ABOVE, PRIOR TO RECEIVING THE EXTRAORDINARY FUNDING IN 2021, PRF'S PERCENTAGE OF PUBLIC SUPPORT SIGNIFICANTLY EXCEEDED 33 1/3%. PRF CONTINUES ALL FUNDRAISING EFFORTS AND EXPECTS TO RETURN TO THE 33 1/3% OF PUBLIC SUPPORT IN THE COMING YEARS.NUMBER OF DONORS FOR THE PAST 10 YEARS:2025 = 1,9902024 = 2,2602023 = 2,1712022 = 2,4322021 = 2,4412020 = 2,7862019 = 3,2452018 = 3,6702017 = 3,8592016 = 4,1462015 = 4,097WITH A PROGRAM RATIO THAT MEETS OR EXCEEDS 80% EACH YEAR, PRF EXPENDS SUBSTANTIALLY ALL OF ITS ANNUAL INCOME FOR ITS EXEMPT PURPOSE AND DEPENDS ON THE FUNDS IT SOLICITS ANNUALLY FROM THE PUBLIC AS WELL AS ITS INVESTMENT INCOME TO SUPPORT THEIR PROGRAMS ON AN ONGOING BASIS. FOR ITS ENTIRE EXISTENCE PRF HAS BEEN RELENTLESSLY FOCUSED ON FINDING TREATMENTS AND THE CURE FOR PROGERIA.IN NOVEMBER 2020, FEDERAL FOOD AND DRUG ADMINISTRATION (FDA) APPROVAL WAS GRANTED FOR LONAFARNIB (ALSO KNOWN BY ITS BRAND NAME ZOKINVY) FOR THE TREATMENT OF PROGERIA. THE PRF-FUNDED CLINICAL DRUG TRIAL INVOLVING LONAFARNIB PROVIDED SIGNIFICANT DATA AND ANALYSIS FOR THE NEW DRUG APPLICATION (NDA) THAT LED TO APPROVAL. AS A DIRECT RESULT OF THIS APPROVAL, AND IN ACCORDANCE WITH THE FEDERAL FOOD, DRUG, AND COSMETIC ACT (FD&C ACT), THE FDA AWARDED A PRIORITY REVIEW VOUCHER (PRV) TO THE SPONSOR OF THIS RARE PEDIATRIC DISEASE PRODUCT NDA. IN 2021, PURSUANT TO A COLLABORATION AGREEMENT WITH THE SPONSOR, PRF RECEIVED PROCEEDS ON THE SALE OF THE PRV IN THE AMOUNT OF $46,493,405. IT IS THE INTENTION OF PRF TO USE THIS EXTRAORDINARY FUNDING TO SUPPORT THE NEXT GENERATION OF RESEARCH AND FUTURE DRUG TRIALS THAT WILL LEAD TO MORE ADVANCED TREATMENTS AND, ULTIMATELY, THE CURE FOR PROGERIA.ANNUALLY, PRF SOLICITS CONTRIBUTIONS FROM THE PUBLIC TO SUPPORT ITS ONGOING PROGRAMS AND SERVICES. FUNDRAISING EFFORTS INCLUDE THE FOLLOWING: A. VOLUNTEER-LED EVENTS (SCHOOL FUNDRAISERS, GOLF TOURNAMENTS, MOTORCYCLE RIDES, ETC.)B. AN ANNUAL 5K RUN, 2-MILE WALK RACE IN PEABODY, MA WITH 300 PARTICIPANTSC. THE ANNUAL FALMOUTH ROAD RACE, WITH A TEAM OF APPROXIMATELY 20 RUNNERSD. THE ANNUAL BOSTON MARATHON, WITH A 2-10 PERSON TEAME. BI-ANNUAL GALA & AUCTION, INCLUDING 350 GUESTSF. MAILING AND SOCIAL MEDIA CAMPAIGNS: MID-YEAR "ONE POSSIBLE AND END OF YEAR "ANNUAL APPEAL", AMONG OTHERS.FUNDS RAISED ARE USED TO SUPPORT THE FOLLOWING PROGRAMS:A. ONGOING CLINICAL DRUG TRIALS AT BOSTON CHILDREN'S HOSPITALB. RESEARCH FOR POTENTIAL FUTURE CLINICAL TRIALSC. THE PRF DIAGNOSTIC TESTING PROGRAMD. THE PRF CELL & TISSUE BANKE. THE PRF MEDICAL & RESEARCH DATABASEF. PRF-ORGANIZED SCIENTIFIC CONFERENCESG. WEBSITE FOR PUBLIC AWARENESS AND COMMUNICATIONH. UPDATING AND DISTRIBUTION OF THE PROGERIA HANDBOOK A TREATMENT GUIDE FOR FAMILIES AND HEALTH CARE PROVIDERS OF THOSE WITH PROGERIAI. THE PRF INTERNATIONAL PROGERIA REGISTRYJ. PUBLIC AWARENESSK. DEVELOPMENT OF A BIOMARKER TO MEASURE THE DISEASE-CAUSING TOXIC PROTEIN, PROGERIN PRF HAS AN ELEVEN-MEMBER BOARD OF DIRECTORS. BOARD MEMBERS' PROFESSIONAL BACKGROUNDS INCLUDE THE LEGAL, ACCOUNTING, PUBLIC RELATIONS, EVENT PLANNING FIELDS AS WELL AS EXECUTIVE LEADERSHIP AND MANAGEMENT OF FOR-PROFIT BUSINESSES. THE BOARD PROVIDES OVERSIGHT OF OPERATIONS AND PROGRAMS TO ENSURE NO ACTIVITIES ARE FOR THE BENEFIT OF PRIVATE INTERESTS.ON AN ANNUAL BASIS, PRF NORMALLY RECEIVES A SUBSTANTIAL PART OF ITS SUPPORT FROM THE GENERAL PUBLIC, GOVERNMENT GRANTS, AND NET INVESTMENT EARNINGS. THE SUPPORT PRF RECEIVES IS USED TO CONTINUE THE MISSION TO DISCOVER TREATMENTS AND THE CURE FOR PROGERIA. IN 2021, PRF RECEIVED AN EXTRAORDINARY SOURCE OF SUPPORT THAT WAS THE RESULT OF DECADES-LONG RESEARCH AND OPERATION OF PRF'S RESEARCH-RELATED PROGRAMS. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 7132 5457 1675 84314 65542 18772 20447 OPERATING LEASE OBLIGATIONS 111699 111699 X 6794879 1757153 805204 2562357 4232522 225494 225494 4458016 4743353 805204 805204 3938149 225494 225494 4163643 PART X, LINE 2: THE ORGANIZATION ACCOUNTS FOR THE UNCERTAINTY IN INCOME TAXES IN ACCORDANCE WITH THE PROVISIONS OF FASB ASC TOPIC NO. 740 INCOME TAXES (ASC 740), WHICH PRESCRIBES A RECOGNITION THRESHOLD OF MORE LIKELY-THAN-NOT, AND A MEASUREMENT ATTRIBUTE FOR ALL TAX POSITIONS TAKEN OR EXPECTED TO BE TAKEN ON A TAX RETURN, IN ORDER FOR THOSE TAX POSITIONS TO BE RECOGNIZED IN THE FINANCIAL STATEMENTS. WHEN NECESSARY, THE ORGANIZATION ACCOUNTS FOR INTEREST AND PENALTIES RELATED TO UNCERTAIN TAX POSITIONS AS PART OF ITS PROVISION FOR INCOME TAXES. THE ORGANIZATION DOES NOT EXPECT THAT UNRECOGNIZED TAX BENEFITS ARISING FROM TAX POSITIONS WILL CHANGE SIGNIFICANTLY WITHIN THE NEXT 12 MONTHS. CANADA 0 0 PROGRAM SERVICES SCIENTIFIC RESEARCH 46252 0 0 0 0 0 0 46252 0 46252 0 0 0 0 0 0 ONEPOSSIBLE ANNUAL CAMPAIGN 125271 117956 7315 6096 ROAD RACE 35710 22535 13175 10979 160981 140491 20490 17075 17075 3415 X 0 0 0 0 0 0 0 1 0 BARBARA NATKE CHIEF BUSINESS OFFICER 315273 0 4250 0 0 0 0 0 0 0 319523 0 0 0 AUDREY GORDON PRESIDENT & EXECUTIVE DIRECTOR 226385 0 30000 0 0 0 0 0 32279 0 288664 0 0 0 PART I, LINE 7 THE PRESIDENT & EXECUTIVE DIRECTOR IS ELIGIBLE TO RECEIVE A DISCRETIONARY PERFORMANCE-BASED BONUS, AS DETERMINED AND APPROVED BY THE BOARD OF DIRECTORS. THE POTENTIAL ANNUAL BONUS IS BASED ON THE ANNUAL PERFORMANCE AS MEASURED AGAINST WEIGHTED PERFORMANCE OBJECTIVES ESTABLISHED EACH YEAR. THE BOARD OF DIRECTORS FORMALLY MEETS IN EXECUTIVE SESSION TO EVALUATE PERFORMANCE AND DETERMINE THE AMOUNT OF ANY BONUS AWARD. THE CHIEF BUSINESS OFFICER'S EMPLOYMENT AGREEMENT INCLUDES A STRUCTURED BONUS ARRANGEMENT TIED TO SPECIFIED PERFORMANCE OBJECTIVES. BECAUSE THE APPLICABLE PERFORMANCE GOAL WAS NOT ACHIEVED IN 2025, NO BONUS WAS EARNED UNDER THE CONTRACTUAL BONUS PLAN. HOWEVER, A DISCRETIONARY BONUS WAS AWARDED UNDER THE ORGANIZATION'S EMPLOYEE INCENTIVE PROGRAM, WHICH APPLIES A STANDARDIZED FORMULA THAT CONSIDERS EMPLOYEE PERFORMANCE, SALARY LEVEL, AND YEARS OF SERVICE. AUDREY GORDON FAMILY MEMBER OF SCOTT BERNS, DIRECTOR 256385 EMPLOYMENT COMPENSATION 0 X 4 95013 MARKET QUOTE 0 0 1 0 SCHEDULE M, PART I, COLUMN (B) THE ORGANIZATION REPORTS THE NUMBER OF SEPARATE NONCASH CONTRIBUTIONS RECEIVED. FOR CONTRIBUTIONS OF SECURITIES, EACH SEPARATE DONOR GIFT IS TREATED AS ONE CONTRIBUTION REGARDLESS OF THE NUMBER OF SHARES TRANSFERRED. DURING THE YEAR, THE ORGANIZATION RECEIVED FOUR SEPARATE STOCK CONTRIBUTIONS FROM THREE DONORS. FORM 990, PART III, LINE 3 THE GRANTS PROGRAM WAS REVAMPED. PRF LEADERSHIP AND THE MRC IMPLEMENTED A CHANGE TO THE GRANTING STRATEGY AS FOLLOWS: THE BIANNUAL CALL FOR APPLICATIONS HAS BEEN REPLACED BY TWO TYPES OF GRANT PATHWAYS: 1) A PROACTIVE PATHWAY WHERE PRF IDENTIFIES A NEED AND SEEKS OUT LABORATORIES BEST SUITED TO CONDUCT THE RESEARCH THAT WILL FILL THAT NEED; 2) AN INVESTIGATOR-DRIVEN PATHWAY WHERE PRF WILL ENTERTAIN RESEARCH PROJECTS BASED ON COMMUNICATIONS INITIATED BY THE INVESTIGATOR THAT INCLUDES A BRIEF ABSTRACT, VIA RESEARCHGRANTS@PROGERIARESEARCH.ORG. THERE IS NO SET DUE DATE FOR THESE COMMUNICATIONS, AND FULL PROPOSALS ARE BY INVITATION-ONLY. PRF WILL ENLIST SUBJECT MATTER EXPERTS TO REVIEW THE FULL RESEARCH PROPOSAL. FORM 990, PART VI, SECTION A, LINE 2 AUDREY GORDON HAS A FAMILY RELATIONSHIP WITH SCOTT BERNS. AUDREY IS THE SISTER OF LESLIE GORDON WHO IS THE VOLUNTEER MEDICAL DIRECTOR OF PROGERIA AND WIFE OF SCOTT BERNS. FORM 990, PART VI, SECTION B, LINE 11B THE 990 IS REVIEWED BY THE PRESIDENT, EXECUTIVE DIRECTOR AND THE TREASURER PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C DISCUSSED AT ANNUAL BOARD MEETINGS. FORM 990, PART VI, SECTION B, LINE 15 SALARIES ARE DETERMINED BY THE INDEPENDENT VOTING MEMBERS AFTER REVIEW OF THE DUTIES PERFORMED AND DATA AS TO COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS. FORM 990, PART VI, SECTION C, LINE 19 ALL DOCUMENTS ARE AVAILABLE ON THE ORGANIZATION'S WEBSITE.